Similar articles

• From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.

  Zenti MG, Altomari A, Lupo MG, Botta M, Bonora E, Corsini A, Ruscica M, Ferri N. Zenti MG, et al. Eur J Prev Cardiol. 2018 Nov;25(17):1843-1851. doi: 10.1177/2047487318792626. Epub 2018 Jul 30. Eur J Prev Cardiol. 2018. PMID: 30058841
• The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report.

  Schettler VJJ, Selke N, Jenke S, Zimmermann T, Schlieper G, Bernhardt W, Heigl F, Grützmacher P, Löhlein I, Klingel R, Hohenstein B, Ramlow W, Vogt A, Julius U; Scientific Board of GLAR for the German Apheresis Working Group. Schettler VJJ, et al. Atherosclerosis. 2024 Nov;398:118601. doi: 10.1016/j.atherosclerosis.2024.118601. Epub 2024 Sep 19. Atherosclerosis. 2024. PMID: 39342791
• How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.

  Hohenstein B, Tselmin S, Bornstein SR, Julius U. Hohenstein B, et al. Atheroscler Suppl. 2017 Nov;30:28-32. doi: 10.1016/j.atherosclerosissup.2017.05.012. Epub 2017 May 31. Atheroscler Suppl. 2017. PMID: 29096851
• Hyperlipoproteinaemia(a) - apheresis and emerging therapies.

  Vogt A. Vogt A. Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):12-17. doi: 10.1007/s11789-017-0083-2. Clin Res Cardiol Suppl. 2017. PMID: 28185213 Free PMC article. Review.
• Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

  Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P; German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN). Schettler VJJ, et al. Atheroscler Suppl. 2017 Nov;30:44-49. doi: 10.1016/j.atherosclerosissup.2017.05.005. Epub 2017 Jun 1. Atheroscler Suppl. 2017. PMID: 29096860 Review.